{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:23:49Z","timestamp":1760059429290,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: The STRIVE study was a multicentre, open-label, real-world clinical trial evaluating the effectiveness of a targeted prescribing pathway for liraglutide 3.0 mg as an adjunct to standard care versus standard care alone in people with obesity attending Specialist Weight Management Services (SWMS) in the UK and Ireland. This post hoc analysis focuses on the standard care arm to explore differences in outcomes between sites, particularly the potential impact of offering meal replacements as part of usual care. Methods: Participants included individuals with a BMI \u2265 35 kg\/m\u00b2 and at least one obesity-related complication who received standard care at five SWMS sites. All sites provided specialist nutrition and exercise counselling; however, only the Dublin site (n = 40) included meal replacements as part of routine care. Baseline characteristics and weight change data were compared between the Dublin and UK cohorts (n = 92) at 52 and 104 weeks. Statistical comparisons were made using appropriate parametric and non-parametric tests. Results: At baseline, the Dublin cohort was significantly older (p &lt; 0.01), had a higher prevalence of hypertension (p &lt; 0.05), and a lower reported incidence of depression\/anxiety (p &lt; 0.05) than the UK cohort. At week 52, the Dublin group achieved greater mean weight loss (\u22126.1%, SD \u00b1 5.7%) compared to the UK cohort (\u22121.3%, SD \u00b1 6.7%, n = 27, p &lt; 0.01). By week 104, Dublin participants maintained a mean weight loss of \u22124.4% (SD \u00b1 5.7%) while UK participants had a mean weight gain of 0.37% (SD \u00b1 7.6%) (p &lt; 0.05). Conclusions: The integration of meal replacements as part of usual care may have contributed to the greater and sustained weight loss observed in the Dublin cohort compared to other SWMS in the UK.<\/jats:p>","DOI":"10.3390\/metabo15060398","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:53:12Z","timestamp":1749786792000},"page":"398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study)"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-4391","authenticated-orcid":false,"given":"Werd","family":"Al-Najim","sequence":"first","affiliation":[{"name":"Clinical Research Centre, St. Vincent\u2019s University Hospital, Elm Park,  Dublin 4, Ireland"},{"name":"Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin 4, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-0653","authenticated-orcid":false,"given":"Babak","family":"Dehestani","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, St. Vincent\u2019s University Hospital, Elm Park,  Dublin 4, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-8269","authenticated-orcid":false,"given":"Ahmed W.","family":"Al-Humadi","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, St. Vincent\u2019s University Hospital, Elm Park,  Dublin 4, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle H.","family":"Bodicoat","sequence":"additional","affiliation":[{"name":"Independent Researcher,  Leicester LE1 7RH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Papamargaritis","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, Leicester General Hospital, College of Life Sciences, University of Leicester, Leicester LE5 4PW, UK"},{"name":"National Institute for Health and Care Research (NIHR), Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester LE5 4PW, UK"},{"name":"Department of Diabetes and Endocrinology, Kettering General Hospital, University Hospitals of Northamptonshire NHS Group, Kettering  NN16 8UZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lean","sequence":"additional","affiliation":[{"name":"School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow G31 2ER,  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology and Obesity (DEO) Clinical Academic Partnership, King\u2019s Health Partners, Guy\u2019s & St Thomas\u2019 Hospital, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Webb","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, Leicester General Hospital, College of Life Sciences, University of Leicester, Leicester LE5 4PW, UK"},{"name":"National Institute for Health and Care Research (NIHR), Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester LE5 4PW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John PH","family":"Wilding","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-9371","authenticated-orcid":false,"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, Leicester General Hospital, College of Life Sciences, University of Leicester, Leicester LE5 4PW, UK"},{"name":"National Institute for Health and Care Research (NIHR), Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester LE5 4PW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, St. Vincent\u2019s University Hospital, Elm Park,  Dublin 4, Ireland"},{"name":"Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin 4, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/obr.12601","article-title":"Commissioning guidance for weight assessment and management in adults and children with severe complex obesity","volume":"19","author":"Welbourn","year":"2018","journal-title":"Obes. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e034137","DOI":"10.1136\/bmjopen-2019-034137","article-title":"Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): Study protocol of an open-label, real-world, randomised, controlled trial","volume":"10","author":"Papamargaritis","year":"2020","journal-title":"BMJ Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s11695-018-3301-1","article-title":"How ethical is our current delivery of care to patients with severe and complicated obesity?","volume":"28","author":"Craig","year":"2018","journal-title":"Obes. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fontbonne, A., Currie, A., Tounian, P., Picot, M.-C., Foulatier, O., Nedelcu, M., and Nocca, D. (2023). Prevalence of overweight and obesity in France: The 2020 obepi-roche study by the \u201cLigue Contre l\u2019Ob\u00e9sit\u00e9\u201d. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030925"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: Potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin. Diabetes"},{"key":"ref_6","first-page":"147","article-title":"PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity","volume":"24","author":"Beba","year":"2022","journal-title":"Diabetes Prim. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/obr.12841","article-title":"Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities","volume":"20","author":"Brown","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud. RDS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int. J. Obes."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2017.01.045","article-title":"Intensive lifestyle intervention for obesity: Principles, practices, and results","volume":"152","author":"Webb","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_11","first-page":"100853","article-title":"Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): A multicentre, open-label, parallel-group, randomized controlled trial","volume":"39","author":"Papamargaritis","year":"2024","journal-title":"Lancet Reg. Health\u2014Eur."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/oby.22303","article-title":"Effectiveness of a total meal replacement program (OPTIFAST program) on weight loss: Results from the OPTIWIN study","volume":"27","author":"Ard","year":"2019","journal-title":"Obesity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ejcn.2011.74","article-title":"Predictors of lifestyle intervention outcome and dropout: The SLIM study","volume":"65","author":"Roumen","year":"2011","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/PPA.S103649","article-title":"Weight loss intervention adherence and factors promoting adherence: A meta-analysis","volume":"10","author":"Lemstra","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e18363","DOI":"10.2196\/18363","article-title":"Relationship between age and weight loss in noom: Quasi-experimental study","volume":"5","author":"DeLuca","year":"2020","journal-title":"JMIR Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s12603-015-0631-8","article-title":"Sarcopenic obesity: An appraisal of the current status of knowledge and management in elderly people","volume":"20","author":"Molino","year":"2016","journal-title":"J. Nutr. Health Aging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: Time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/6\/398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:51:08Z","timestamp":1760032268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/6\/398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["metabo15060398"],"URL":"https:\/\/doi.org\/10.3390\/metabo15060398","relation":{},"ISSN":["2218-1989"],"issn-type":[{"type":"electronic","value":"2218-1989"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}